Company Overview - Moderna is a commercial-stage biotech founded in 2010, with its IPO in December 2018. The company's mRNA technology gained rapid validation through its COVID-19 vaccine, authorized in the U.S. in December 2020. As of August 2025, Moderna has 35 mRNA development candidates in clinical studies across various therapeutic areas, including infectious diseases, oncology, cardiovascular diseases, and rare genetic diseases [8]. Market Sentiment - Recent options trading indicates a bearish sentiment among deep-pocketed investors towards Moderna, with 55% of notable options leaning bearish and only 33% bullish. This shift in sentiment is significant and suggests that market players should pay attention [1][2]. - The total options activity for Moderna has been extraordinary, with 12 put options totaling $1,840,896 and 6 call options amounting to $311,479 [2]. Price Targets and Trading Activity - Whales have been targeting a price range for Moderna between $30.0 and $50.0 over the last three months, based on the volume and open interest of options contracts [3]. - The average open interest for Moderna options is 531.31, with a total trading volume of 9,720.00. The trading activity has been concentrated within the strike price corridor of $30.0 to $50.0 over the past 30 days [4]. Recent Trading Data - Significant options trades include bearish put options with a total trade value of $1.1 million at a strike price of $42.00, and bullish put options valued at $300,000 with a strike price of $47.00. Additionally, there are neutral and bearish call options with varying trade values and strike prices [7]. Current Market Standing - As of the latest data, Moderna's trading volume is 3,713,575, with the stock price down by 2.71% at $47.39. Analysts have recently adjusted their ratings, with one expert from UBS revising the price target down to $34.0, indicating a neutral stance on the stock [10][11].